- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kyntra Bio Inc (KYNB)
The Kyntra Bio share price today is 7.230, view NASDAQ KYNB stock exchange data. Track the latest Kyntra Bio share price with real-time updates on KYNB stock performance including market cap, day range, 52-week range and dividend yield. Access KYNB charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.160
7.390
52 wk Range
6.320
12.600
KYNB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.1607.390
52 wk Range
6.32012.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KYNB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
39.000
Upside
+439.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Kyntra Bio stock rises on roxadustat MDS trial data
- Investing.com
- Form 4 Kyntra Bio Inc For: 17 June
- Investing.com
- Form 4 Kyntra Bio Inc For: 17 June
- Investing.com
- Form 8K Kyntra Bio Inc For: 16 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 39.000
(+439.42% Upside)
Kyntra Bio Inc Earnings Call Summary for Q2/2025
- FibroGen reports Q2 2025 EPS of -$1.88, missing forecast of -$0.09; revenue falls short at $1.3M vs $2.88M expected
- Stock drops 3.9% to $8.71 post-earnings; company valued at $34M market cap, deemed overvalued by InvestingPro analysis
- Operating costs decrease 72% YoY; R&D expenses down 82%; company extends cash runway to 2028
- Full-year 2025 revenue guidance set at $6M-$8M; Phase II trial for prostate cancer treatment FG3246 to begin Q3 2025
- CEO expresses optimism about clinical programs; CFO highlights financial strategies to benefit shareholders
Last Updated: 12-08-2025, 03:16 am
Read Full TranscriptEarnings
Latest Release
11-05-2026
EPS / Forecast
-3.76 / -0.21
Revenue / Forecast
3.7M / 1.51M
Compare KYNB to Peers and Sector
Metrics to compare | KYNB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKYNBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | 12.2x | −0.4x | |
PEG Ratio | 0.00 | 0.05 | 0.00 | |
Price/Book | −0.7x | 3.4x | 2.6x | |
Price / LTM Sales | 3.9x | 4.0x | 3.0x | |
Upside (Analyst Target) | - | 95.2% | 50.8% | |
Fair Value Upside | Unlock | 4.3% | 9.4% | Unlock |
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Kyntra Bio (KYNB) Share Price Today?
The Kyntra Bio share price today is 7.230.
What is the current Kyntra Bio (KYNB) share price and day range?
As of 18-07-2026, the Kyntra Bio share price is 7.230, with a previous close of 7.390. The share price has ranged from 7.160 to 7.390 today, while the 52-week range spans from 6.320 to 12.600.
What Is the Kyntra Bio Market Cap?
As of today, Kyntra Bio market cap is 29.270M.
What Is the Kyntra Bio (KYNB) Share Price Target?
The average 12-month share price target for Kyntra Bio is 39.000, with a high estimate of 43 and a low estimate of 35. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +439.42% Upside potential.
What Is Kyntra Bio's Earnings Per Share (TTM)?
The Kyntra Bio EPS (TTM) is -13.984.
When Is the Next Kyntra Bio Earnings Date?
Kyntra Bio will release its next earnings report on 10-08-2026.
From a Technical Analysis Perspective, Is KYNB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Kyntra Bio Trade On?
Kyntra Bio is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Kyntra Bio?
The stock symbol for Kyntra Bio is "KYNB."
How Many Times Has Kyntra Bio Stock Split?
Kyntra Bio has split 1 times.
How Many Employees Does Kyntra Bio Have?
Kyntra Bio has 34 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.